Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIPnew Extension Study in Cystic Fibrosis
NCT00982930Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2009
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of tobramycin in cystic fibrosis (CF) and Pseudomonas aeruginosa infection, sponsored by Novartis. Primary endpoints: Percentage of Participants With Adverse Events (AEs) up to 25 weeks, Percentage of Participants With Serious Adverse Events (SAEs) up to 29 weeks and 5 more. Started Aug 2009; status: completed.
02
Drugs
tobramycin
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT00982930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00982930.